Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tryptamine Therapeutics ( (AU:TYP) ) has issued an announcement.
Tryptamine Therapeutics has announced the date for its 2025 Annual General Meeting, which will be held on November 13, 2025. The company is advancing its clinical trials with TRP-8803, a novel formulation of psilocin, showing promising results in reducing binge eating episodes and addressing fibromyalgia and irritable bowel syndrome. These developments could enhance the company’s position in the biotechnology industry by offering new treatment options for conditions with significant unmet needs.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited is a clinical-stage biotechnology company specializing in the development of proprietary formulations of psilocin for use in combination with psychotherapy. Their focus is on addressing diseases with unmet medical needs, with a lead program, TRP-8803, aimed at improving the administration of psilocin. The company has completed Phase 2a clinical trials for binge eating disorder and fibromyalgia, and has initiated a trial for irritable bowel syndrome.
Average Trading Volume: 1,788,674
Technical Sentiment Signal: Sell
Current Market Cap: A$46.08M
For a thorough assessment of TYP stock, go to TipRanks’ Stock Analysis page.